HLS Net Income Per Share from 2010 to 2026

HLS Stock  CAD 4.65  0.05  1.06%   
HLS Therapeutics Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to grow to -0.67 this year. During the period from 2010 to 2026, HLS Therapeutics Net Loss quarterly data regression pattern had sample variance of  0.42 and median of (0.41). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(0.71)
Current Value
(0.67)
Quarterly Volatility
0.64587723
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
  
This module can also supplement various HLS Therapeutics Technical models . Check out the analysis of HLS Therapeutics Correlation against competitors.

Latest HLS Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of HLS Therapeutics over the last few years. It is HLS Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

HLS Net Income Per Share Regression Statistics

Arithmetic Mean(0.17)
Geometric Mean0.47
Coefficient Of Variation(389.66)
Mean Deviation0.55
Median(0.41)
Standard Deviation0.65
Sample Variance0.42
Range1.9517
R-Value(0.88)
Mean Square Error0.1
R-Squared0.78
Slope(0.11)
Total Sum of Squares6.67

HLS Net Income Per Share History

2025 -0.71
2024 -0.62
2023 -0.85
2022 -0.73
2021 -0.41
2020 -0.48
2019 -0.67

About HLS Therapeutics Financial Statements

HLS Therapeutics investors utilize fundamental indicators, such as Net Income Per Share, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(0.71)(0.67)

Other Information on Investing in HLS Stock

HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.